Literature DB >> 2210078

Limited duration of remission of insulin dependency in children with recent overt type I diabetes treated with low-dose cyclosporin.

P F Bougnères1, P Landais, C Boisson, J C Carel, N Frament, C Boitard, J L Chaussain, J F Bach.   

Abstract

Preliminary data from our group indicated that cyclosporin A induced frequent remissions of insulin dependency in a group of 40 insulin-dependent (type I) diabetic children if given at the onset of clinical manifestations of diabetes. We report a 2-yr analysis of the response to cyclosporin A in the group of 81 patients included in the initial study. As observed before, a remission could be obtained in most of the patients (65%) in association with a shorter duration of symptoms, less severe hyperglycemia, lower incidence of ketoacidosis, and higher plasma C-peptide concentrations. All remissions ended during the follow-up period after a mean +/- SE duration of 316 +/- 21 days (range 31-850 days). Two parameters were linked to the duration of remissions: the mean circulating level of cyclosporin during the first 3 mo and the duration of prediagnostic polyuria. We were unable to relate the end of a remission to variations in the cyclosporin regimen, titer of autoantibodies, or progression of beta-cell failure. The euglycemic clamp technique revealed that insulin sensitivity decreases with time in patients not taking insulin. At 24 mo, the patients who had a remission of insulin dependency had better glycemic control, lower insulin dosages, and C-peptide levels two- to threefold higher than the nonremission patients and four- to sixfold higher than the historical control subjects. The cyclosporin regimen was well tolerated over the observed period: more specifically, serum creatinine remained unchanged, and kidney biopsies performed at 18-24 mo of treatment were within normal limits.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2210078     DOI: 10.2337/diab.39.10.1264

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  51 in total

Review 1.  Genetic vaccination for re-establishing T-cell tolerance in type 1 diabetes.

Authors:  Mark C Johnson; Bo Wang; Roland Tisch
Journal:  Hum Vaccin       Date:  2011-01-01

2.  The use of FK 506 in new-onset type I diabetes in man.

Authors:  P B Carroll; A G Tzakis; C Ricordi; H R Rilo; K Abu-Elmagd; N Murase; Y J Zeng; R Alejandro; D Mintz; T E Starzl
Journal:  Transplant Proc       Date:  1991-12       Impact factor: 1.066

3.  Parameters influencing antigen-specific immunotherapy for Type 1 diabetes.

Authors:  Bo Wang; Roland Tisch
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

4.  Parameters influencing antigen-specific immunotherapy for type 1 diabetes.

Authors:  Bo Wang; Roland Tisch
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

Review 5.  Stem Cell Therapies for Treating Diabetes: Progress and Remaining Challenges.

Authors:  Julie B Sneddon; Qizhi Tang; Peter Stock; Jeffrey A Bluestone; Shuvo Roy; Tejal Desai; Matthias Hebrok
Journal:  Cell Stem Cell       Date:  2018-06-01       Impact factor: 24.633

Review 6.  Surrogate end points in the design of immunotherapy trials: emerging lessons from type 1 diabetes.

Authors:  Bart O Roep; Mark Peakman
Journal:  Nat Rev Immunol       Date:  2010-02       Impact factor: 53.106

Review 7.  Immunomodulatory therapy to preserve pancreatic β-cell function in type 1 diabetes.

Authors:  Frank Waldron-Lynch; Kevan C Herold
Journal:  Nat Rev Drug Discov       Date:  2011-06       Impact factor: 84.694

8.  Prevention of insulin-dependent diabetes mellitus--wishful thinking, or reality?

Authors:  J Palmer
Journal:  West J Med       Date:  1996-03

Review 9.  Targeting Innate Immunity for Type 1 Diabetes Prevention.

Authors:  James C Needell; Danny Zipris
Journal:  Curr Diab Rep       Date:  2017-09-27       Impact factor: 4.810

Review 10.  Therapeutic vaccination using CD4+CD25+ antigen-specific regulatory T cells.

Authors:  Jeffrey A Bluestone; Qizhi Tang
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-20       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.